Paul Hastings advised FACT II Acquisition Corp. on the offering. FACT II Acquisition Corp. announced the pricing of its initial public offering of 17,500,000 units at...
You must be a Standard 1 Year member to access this content.
Paul Hastings advised Viking Therapeutics on the offering. Viking Therapeutics, Inc. (Nasdaq: VKTX) executed its underwritten offering of $632.5 million of shares of its common stock....
You must be a Standard 1 Year member to access this content.
Paul Hastings LLP advised Jasper Therapeutics, Inc., while DLA Piper advised the underwriters. Jasper Therapeutics, Inc. (Nasdaq: JSPR), a clinical-stage biotechnology company focused on developing novel...
You must be a Standard 1 Year member to access this content.
